PTK2 and pancreatic neoplasm: The recently developed FAK inhibitor GSK2256098 has also been tested in clinical trials (194, 195) (NCT01138033, NCT02428270) and has completed phase II clinical trials in pancreatic cancer (194) (NCT02428270).